Navigation Links
Medtronic Device Proves Effective in Parkinson’s Diseas

A recent study has shown that Medtronic Inc.'s (MDT) Activa brain stimulation device, in combination with medication is shown to improve motor functions// as well as quality of life in patients with advanced Parkinson's disease more than in patients receiving only medication.

The study was published in Thursday's issue of the New England Journal of Medicine.

In 2002 the Food and Drug Administration had approved the Activa deep brain stimulation therapy to treat Parkinson's. While earlier studies mainly looked at brain stimulation in treating motor functions, this study looked at quality of life as a main endpoint, in addition to motor functions.

Dr. Richard Kuntz, president of the neurological division of the Minneapolis medical-device company told that the results validate Activa's value by providing additional clinical evidence from this study that was more rigorous than past studies.

This six-month study was conducted on 156 patients below 75 years of age who have had Parkinson's for at least five years and suffer from impaired mobility despite medication. During the study all the patients received medication, and half received neurostimulation treatment with the Activa device.

Patients receiving neurostimulation saw a 25% improvement in quality of life and a 41% improvement in motor functions, compared with virtually no change in patients receiving only medication.

The study reports, "In carefully selected patients, neurostimulation of the subthalamic nucleus is a powerful treatment that alleviates the burden of advanced Parkinson's disease."

The Activa device includes electrodes surgically implanted in the brain and connected by an extension under the skin to a neurostimulator implanted near the collarbone. The electrical stimulation can be noninvasively adjusted.

The study was conducted by German and Austrian researchers. Medtronic has awarded some of the researche rs including lead author Dr. Gunther Deuschl, with compensation and research grants.

Although the German government sponsored the study, Medtronic coordinated investigator meetings and payedfor supplemental insurance for the study's patients.

Dr. C. Warren Olanow, neurology department chairman at New York's Mount Sinai School of Medicine and leader of clinical research that led to Activa's FDA approval for Parkinson's, said the study achieved its endpoints and "further affirms this treatment is effective."

Of the 13 patients who reported severe adverse side effects, 10 received neurostimulation and three received only medication. Of the four deaths, three were in the neurostimulation group and one in the medication-only group.


NLA
'"/>




Related medicine news :

1. Medtronic’s Insulin Pump Receives Regulatory Approva
2. Injection supports Heart Devices
3. New Heart-Screening Device ,An Accurate Predictor Of Heart Disease
4. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
5. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
6. New Implantable Device That Can Keep The Heart Ticking
7. Making MRIs Safe for Patients With Implantable Heart Devices
8. Researchers Develop Device For Detecting Atherosclerotic Plaques
9. A Cheap Device to Stop Snoring from New Zealand
10. Scientists Concerned Over Increasing Malfunction Of Heart Devices
11. Device For Improving Bone Mass In Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2016)... SC (PRWEB) , ... May 27, 2016 , ... ... a line of classic American timber frame barn kits, which can be found on ... are inspired by historic American barn plans, and they highlight the craftsmanship of timber ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... An ... bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It ... leading advocates, associations and industry leaders such as Bioness. , As patients ...
(Date:5/27/2016)... , ... May 27, 2016 , ... ... installment is bolstered by inspiring human interest stories, courtesy of leaders in the ... and tech within the industry, from leading advocates and associations—namely Jones & Bartlett ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... the pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center ... proof of successfully certified products, services and staff. , Validation Center is ISO17025 ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology: